Effects of Whole-Body Vibration on Heart Rate Variability During Post-Exercise Recovery (WBV-HRV)

November 6, 2026 updated by: Hamza Budak

Effects of Whole-Body Vibration Versus Passive Recovery on Frequency-Domain Heart Rate Variability Following High-Intensity Exercise: A Randomized Crossover Trial

This study aims to investigate the acute effects of whole-body vibration (WBV) and passive recovery on heart rate variability (HRV) following high-intensity intermittent exercise in male soccer players.

Ten male soccer players will participate in a randomized, two-period crossover study. Each participant will complete two experimental sessions separated by a seven-day washout period. During each session, participants will perform the Yo-Yo Intermittent Recovery Test Level 1 until exhaustion, followed by either 15 minutes of seated whole-body vibration or 15 minutes of seated passive recovery.

During the WBV condition, participants will remain seated with their knees flexed at approximately 90 degrees and their bare feet positioned on a vibration platform operating at 35 Hz with a peak-to-peak amplitude of 2 mm. During passive recovery, participants will remain seated without vibration.

Heart rate variability will be continuously recorded throughout the exercise test and the entire 15-minute recovery period using a chest-strap heart rate sensor. Frequency-domain HRV parameters, including very-low-frequency (VLF), low-frequency (LF), and high-frequency (HF) power, will be analyzed.

The study will compare the autonomic responses associated with the two recovery methods to determine whether seated whole-body vibration produces different short-term HRV responses compared with passive recovery.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Not yet recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

This study is designed as a randomized, two-period crossover trial to examine the acute effects of whole-body vibration (WBV) and passive recovery on frequency-domain heart rate variability (HRV) following exhaustive intermittent exercise.

Ten male soccer players will participate in the study. Participants will be randomly assigned to one of two intervention sequences: WBV followed by passive recovery (AB) or passive recovery followed by WBV (BA). A seven-day washout period will separate the experimental sessions to minimize potential carryover effects.

At each experimental session, participants will complete the Yo-Yo Intermittent Recovery Test Level 1 until voluntary exhaustion. Following exercise, participants will undergo a 15-minute recovery intervention according to their assigned sequence.

During the WBV intervention, participants will sit on a chair with their knees flexed at approximately 90 degrees and their bare feet placed on a vertical vibration platform operating at 35 Hz with a peak-to-peak displacement of 2 mm. During the passive recovery intervention, participants will remain seated in a comparable position with their feet resting on the floor and without vibration exposure.

Heart rate variability will be recorded continuously throughout the exercise test and the complete 15-minute recovery period using a Polar H10 chest-strap sensor. HRV data will be processed using Kubios HRV software to obtain frequency-domain parameters, including VLF, LF, and HF power.

The primary objective is to compare frequency-domain HRV responses between WBV and passive recovery conditions. Statistical analyses will account for the paired crossover design and evaluate differences between recovery conditions.

The findings are expected to contribute to the understanding of acute autonomic responses to whole-body vibration as a post-exercise recovery intervention in soccer players.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
10

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years to 40 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • Male soccer players within the predefined eligible age range.
  • Regular participation in soccer training.
  • Ability to complete the Yo-Yo Intermittent Recovery Test Level 1.
  • Willingness to participate in both experimental sessions.
  • Provision of written informed consent.

Exclusion Criteria:

  • Known cardiovascular, neurological, or musculoskeletal disorders that could affect exercise performance or heart rate variability.
  • Current injury or illness preventing maximal exercise.
  • Use of medications known to influence autonomic nervous system activity or heart rate variability.
  • Any contraindication to whole-body vibration exposure.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Sequence AB (WBV → Passive Recovery)

Participants assigned to Sequence AB will undergo whole-body vibration (WBV) recovery during the first experimental period, followed by passive recovery during the second period. A seven-day washout period will separate the two sessions. Both recovery interventions will last 15 minutes and will be performed in a seated position following the Yo-Yo Intermittent Recovery Test Level 1. During WBV recovery, participants will remain seated with their feet placed on the vibration platform, operating at 35 Hz and 2 mm peak-to-peak amplitude.
Device: Whole-Body Vibration (WBV)

Participants assigned to the whole-body vibration (WBV) intervention will undergo a 15-minute recovery session immediately following the Yo-Yo Intermittent Recovery Test Level 1. During the intervention, participants will remain seated on a chair with their knees flexed at approximately 90 degrees and their bare feet placed on a vertical vibration platform. The platform will operate at a frequency of 35 Hz and a peak-to-peak amplitude of 2 mm. Heart rate variability will be continuously recorded throughout the 15-minute recovery period to evaluate autonomic nervous system responses.

Other: Passive Recovery

Participants assigned to the passive recovery intervention will undergo a 15-minute seated recovery session immediately following the Yo-Yo Intermittent Recovery Test Level 1. During this period, participants will remain seated on a chair with their feet resting on the floor, without receiving whole-body vibration or any other active recovery intervention. Heart rate variability will be continuously recorded throughout the 15-minute recovery period to evaluate autonomic nervous system responses.
Experimental: Sequence BA (Passive Recovery → WBV)

Participants assigned to Sequence BA will undergo passive recovery during the first experimental period, followed by whole-body vibration (WBV) recovery during the second period. A seven-day washout period will separate the two sessions. Both recovery interventions will last 15 minutes and will be performed in a seated position following the Yo-Yo Intermittent Recovery Test Level 1. During passive recovery, participants will remain seated with their feet resting on the floor. During WBV recovery, participants will remain seated with their feet placed on the vibration platform, operating at 35 Hz and 2 mm peak-to-peak amplitude.
Device: Whole-Body Vibration (WBV)

Participants assigned to the whole-body vibration (WBV) intervention will undergo a 15-minute recovery session immediately following the Yo-Yo Intermittent Recovery Test Level 1. During the intervention, participants will remain seated on a chair with their knees flexed at approximately 90 degrees and their bare feet placed on a vertical vibration platform. The platform will operate at a frequency of 35 Hz and a peak-to-peak amplitude of 2 mm. Heart rate variability will be continuously recorded throughout the 15-minute recovery period to evaluate autonomic nervous system responses.

Other: Passive Recovery

Participants assigned to the passive recovery intervention will undergo a 15-minute seated recovery session immediately following the Yo-Yo Intermittent Recovery Test Level 1. During this period, participants will remain seated on a chair with their feet resting on the floor, without receiving whole-body vibration or any other active recovery intervention. Heart rate variability will be continuously recorded throughout the 15-minute recovery period to evaluate autonomic nervous system responses.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Very Low Frequency (VLF) Power
Time Frame: During the exercise test and the subsequent 15-minute recovery period in each experimental session.

Very low frequency (VLF) power is a frequency-domain parameter of heart rate variability (HRV), expressed in ms². HRV will be continuously recorded using a Polar H10 chest strap during the entire exercise test and the 15-minute recovery period. VLF power will be analyzed using Kubios HRV software to assess autonomic responses under whole-body vibration and passive recovery conditions.
During the exercise test and the subsequent 15-minute recovery period in each experimental session.
Low Frequency (LF) Power
Time Frame: During the exercise test and the subsequent 15-minute recovery period in each experimental session.

Low frequency (LF) power is a frequency-domain parameter of heart rate variability (HRV), expressed in ms². HRV will be continuously recorded using a Polar H10 chest strap during the entire exercise test and the 15-minute recovery period. LF power will be analyzed using Kubios HRV software to evaluate autonomic responses under whole-body vibration and passive recovery conditions.
During the exercise test and the subsequent 15-minute recovery period in each experimental session.
High Frequency (HF) Power
Time Frame: During the exercise test and the subsequent 15-minute recovery period in each experimental session.

High frequency (HF) power is a frequency-domain parameter of heart rate variability (HRV), expressed in ms², and is commonly used as an indicator of cardiac parasympathetic modulation. HRV will be continuously recorded using a Polar H10 chest strap during the entire exercise test and the 15-minute recovery period. HF power will be analyzed using Kubios HRV software to compare responses between whole-body vibration and passive recovery conditions.
During the exercise test and the subsequent 15-minute recovery period in each experimental session.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Hamza Budak

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
November 17, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
November 24, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
November 24, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
November 6, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 6, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
November 12, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
November 12, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 6, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
November 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • ASU-HRV-WBV-2026-01

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data will not be made publicly available due to participant confidentiality and data protection considerations. Only aggregated and anonymized study results will be reported in scientific publications.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings